A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2

Bone morphogenetic protein-2 (BMP-2) is currently the only Food and Drug Administration (FDA)-approved osteoinductive growth factor used as a bone graft substitute. However, with increasing clinical use of BMP-2, a growing and well-documented side effect profile has emerged. This includes postoperative inflammation and associated adverse effects, ectopic bone formation, osteoclast-mediated bone resorption, and inappropriate adipogenesis. Several large-scale studies have confirmed the relative frequency of adverse events associated with the clinical use of BMP-2, including life-threatening cervical spine swelling. In fact, the FDA has issued a warning of the potential life-threatening complications of BMP-2.…

• MT
  Musculoskeletal Transplant Foundation

  Award: K08 AR068316
• NI
  National Institutes of Health

  Award: K08 AR068316
• NI
  National Institute of Arthritis and Musculoskeletal and Skin Diseases

  Awards: K08 AR068316, R01 AR061399, R01 AR066782